With the advancements that GMED has made, why is your stock not moving? What does the FDA have to say about your research and are they on board? I continue to gobble up this stock but continue to scratch my head.
So do I, believe me!
Technically, GenoMed operates outside the FDA’s jurisdiction. We’re just one set of doctors recommending to others how to practice. We don’t manufacture any drugs. If we did, we’d be inside the FDA’s jurisdiction.
If existing drugs don’t do the job for cancer, then we’ll have to look into new drug discovery. We’re just at the beginning of testing our novel approach to treating cancer, which is to target host (germline) genes instead of tumor-specific genes.
Dave Moskowitz MD
CEO & Chief Med Officer